Trust Size
$173M
Peak Price
$129.00
Current Price
$3.93
Return
-60.7%
Price Journey
What Happened
SAB Biotherapeutics is a clinical-stage biopharmaceutical company that uses genetically engineered cattle to produce fully human polyclonal antibodies for treating infectious diseases.
SAB Biotherapeutics went public through a SPAC merger and trades under SABS. The company's novel DiversitAb platform uses transchromosomic cattle whose immune systems produce human antibodies when exposed to disease targets. SAB gained attention during COVID-19 for its potential therapeutic approach but has struggled to advance programs commercially, with the stock declining sharply and a reverse stock split executed.
Timeline
2021-01-04
S-1 Registration Filed
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1833214
Total SEC Filings
400
State of Incorporation
DE
Last Filing Date
2026-03-19
Business Location
Miami Beach, FL
Trust/Asset Size
$173M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for SAB Biotherapeutics